

VT

PATENTES

BIOTECNOLOGÍA SANITARIA

Degeneración macular
Diabetes
Sistema nervioso
Sistema inmune

33



**Vigilancia
Tecnológica**
3^{er} trimestre 2021

NIPO: 116-19-008-3

Este Boletín de Vigilancia Tecnológica en Biotecnología aplicada al sector sanitario surge del trabajo conjunto entre la Oficina Española de Patentes y Marcas (OEPM) y ASEBIO como miembro de la Plataforma Tecnológica Española de Mercados Biotecnológicos, y se encuadra dentro de una de las actividades de colaboración que la OEPM viene llevando a cabo con las referidas Plataformas para hacer llegar a las empresas, investigadores, y organizaciones que las integran una selección de las patentes más recientemente publicadas en determinados sectores tecnológicos.

Estos Boletines trimestrales, como el resto de los elaborados por la OEPM, ofrecen una información puntual, esquemática y de rápida lectura sobre una selección de las últimas patentes biotecnológicas publicadas en el

mundo relativas a cuatro líneas de investigación concretas: Sistema Nervioso, Sistema Inmune, Diabetes y Degeneración Macular. A través del número de publicación de cada patente, un enlace permite consultar el documento completo e incluso poder disponer de una traducción de la descripción realizada con la herramienta Patent translate.


También incluyen noticias sobre actividades realizadas por la OEPM que puedan resultar de interés a los usuarios. Si se desea recibir este Boletín periódicamente basta con cumplimentar el correspondiente [formulario de suscripción](#).

Se puede acceder al listado de solicitudes de patentes analizadas pulsando sobre las imágenes que aparecen a continuación.


Contenido




DEGENERACIÓN
MACULAR



DIABETES



SISTEMA NERVIOSO



SISTEMA INMUNE

Degeneración Macular

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2021157681	RIBOMIC INC [JP]	Therapeutic agent for subretinal hyperreflective material or retinal disorders accompanying subretinal hyperreflective material
WO2021129658	INNOVENT BIOLOGICS SUZHOU CO LTD [CN]	Application of fusion protein in treating age-related macular degeneration
WO2021125263	NAT UNIV CORPORATION OKAYAMA UNIV [JP]; SOWAKAI MEDICAL FOUND [JP]	Use of antibody-drug conjugates and antibodies for drug delivery
WO2021113591	REGENERON PHARMA [US]	VEGF mini-traps and methods of use thereof
WO2021112926	REGENERON PHARMA [US]	Anti-VEGF protein compositions and methods for producing the same
WO2021112924	REGENERON PHARMA [US]	Anti-VEGF protein compositions and methods for producing the same
WO2021113390	SHAPE THERAPEUTICS INC [US]	Compositions for treatment of diseases

Diabetes

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2021177333	UNIV SHINSHU [JP]	Adiponectin quantification method and analysis reagent for use in said method
WO2021174201	UNIV PENNSYLVANIA [US]	Tissue culture media for survival and engraftment of human pancreatic islets
WO2021162532	G2GBIO INC [KR]	Pharmaceutical composition comprising sustained-release microspheres including GLP-1 analogue or pharmaceutically acceptable salt thereof
WO2021153365	OTSUKA PHARMA FACTORY INC [JP]	Method for producing pancreatic islet-containing capsule
WO2021150011	UNIV KEIMYUNG IACF [KR]	Biomarker for early diagnosis of diabetes or diabetic complications and use thereof
WO2021145675	MDIMUNE INC [KR]; SEOUL NAT UNIV R&DB FOUNDATION [KR]	Cell-derived vesicles comprising target protein and method for producing same
WO2021146632	SECOND GENOME INC [US]; RAVICHANDAR JAYAMARY DIVYA [US]; KAWANA SHOKO [US]; YAMAMOTO MITSUKO LYNN [US]	Methods and compositions for treating type 2 diabetes
WO2021145435	UNIV OSAKA [JP]; MITSUBISHI TANABE PHARMA CORP [JP]	Prophylactic or therapeutic agent for dementia
WO2021145432	UNIV OSAKA [JP]; MITSUBISHI TANABE PHARMA CORP [JP]	Agent for prevention or treatment of diabetic autonomic neuropathy
WO2021143879	SHANGHAI BENEMAE PHARMACEUTICAL CORP [CN]	Combinational therapy comprising GLP-1 and/or GLP-1 analogs, and insulin and/or insulin analogs
WO2021143810	ZHUHAI UNITED LABORATORIES CO LTD [CN]	Polypeptide compound and use thereof
WO2021143073	SHENZHEN JYMED TECH CO LTD [CN]	Preparation method for semaglutide
WO2021142733	SHANGHAI BENEMAE PHARMACEUTICAL CORP [CN]	Combinational therapy comprising GLP-1 and/or GLP-1 analogs, and insulin and/or insulin analogs
WO2021139744	BEIJING QL BIOPHARMACEUTICAL CO LTD [CN]	Conjugates of fusion proteins of GLP-1 and FGF21
WO2021139763	SHANGHAI HANSOH BIOMEDICAL CO LTD [CN]; JIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD [CN]	FGF21 mutant protein and fusion protein thereof
WO2021136303	GAN & LEE PHARMACEUTICALS [CN]	Long-acting GLP-1 compound

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2021136302	GAN & LEE PHARMACEUTICALS [CN]	Insulin derivative
WO2021136293	GAN & LEE PHARMACEUTICALS [CN]	Insulin derivative
WO2021136296	GAN & LEE PHARMACEUTICALS [CN]	Insulin derivative
WO2021138302	UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION [US]	Intrapancreatic M2 polarization of macrophages to treat type 1 diabetes
WO2021136223	BEIJING QL BIOPHARMACEUTICAL CO LTD [CN]	Fusion proteins of GLP-1 and GDF15 and conjugates thereof
WO2021137494	SAHMYOOK UNIV INDUSTRY ACADEMIC COOPERATION FOUNDATION [KR]	Composition for preventing or treating diabetes comprising <i>Butyricimonas sp.</i> strain as active ingredient
WO2021133644	MERCK SHARP & DOHME [US]; BIANCHI ELISABETTA [IT]; DENG QIAOLIN [US]; LIN SONGNIAN [US]; ORVIETO FEDERICA [IT]; PALANI ANANDAN [US]; PESSI ANTONELLO [IT]; SAWYER TOMI K [US]	Stapled triazole co-agonists of the glucagon and GLP-1 receptors
WO2021133643	MERCK SHARP & DOHME [US]; BIANCHI ELISABETTA [IT]; DENG QIAOLIN [US]; LIN SONGNIAN [US]; ORVIETO FEDERICA [IT]; PALANI ANANDAN [US]; PESSI ANTONELLO [IT]; SAWYER TOMI K [US]	Stapled olefin co-agonists of the glucagon and GLP-1 receptors
WO2021132453	UNIV KOBE NAT UNIV CORP [JP]; KANEKA CORP [JP]	Capillary blood vessel disorder inhibiting agent, capillary blood vessel disorder ameliorating agent, and capillary angiogenesis accelerating agent
WO2021129779	LI YING [CN]	Novel amphiphilic protein, preparation method therefor and use thereof
WO2021133642	MERCK SHARP & DOHME [US]; BIANCHI ELISABETTA [IT]; CARRINGTON PAUL E [US]; DENG QIAOLIN [US]; LIN SONGNIAN [US]; ORVIETO FEDERICA [IT]; PALANI ANANDAN [US]; PESSI ANTONELLO [IT]; SAWYER TOMI K [US]	Stapled lactam co-agonists of the glucagon and GLP-1 receptors
WO2021132329	UNIV OSAKA [JP]; INNATE CELL THERAPY INC [JP]	Body fat reducing agent and method for screening substance having body fat reducing effect
WO2021119019	EMPIRICO INC [US]	Oligonucleotides for treatment of angiotensin like 4 (ANGPTL4) related diseases
WO2021113551	BAYLOR COLLEGE MEDICINE [US]; TVARDI THERAPEUTICS INC [US]	Therapeutic compounds for methods of use in insulin resistance
WO2021110071	UNIV HONG KONG POLYTECHNIC [CN]; UNIV HONG KONG CHINESE [CN]	Methods for inducing intermittent fasting and modulating autophagy

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2021178565	ADITXT INC [US]; UNIV LELAND STANFORD JUNIOR [US]	Methods of treating hyperglycemia and suppressing onset of type 1 diabetes
WO2021175974	SANOFI SA [FR]	Peptides as selective GIP receptor agonists
WO2021170504	LING CHARLOTTE [SE]; GARCIA CALZON SONIA [ES]; PERFILYEV ALEXANDER [SE]	DNA methylation level of specific CpG sites for prediction of glycemic response and tolerance to metformin treatment in type 2 diabetic patients
WO2021170848	ACAD MEDISCH CT [NL]; UNIV WAGENINGEN [NL]	Intervention strategy for prevention or treatment of diabetes mellitus, autoimmune disease, inflammatory disease or cardiovascular disease
WO2021150673	LILLY CO ELI [US]	GIP/GLP1 co-agonist compounds
WO2021152579	NAT INST BIOTECHNOLOGY NEGEV LTD [IL]; B G NEGEV TECHNOLOGIES AND APPLICATIONS LTD AT BEN GURION UNIV [IL]	Peptides useful in preservation and/or restoration of functional pancreatic islets and in treating diabetes
WO2021152184	ADOCIA [FR]	Compositions comprising at least an amylin receptor agonist and a GLP-1 receptor agonist
WO2021127493	DANA FARBER CANCER INST INC [US]	Structurally-stabilized glucagon-like peptide 1 peptides and uses thereof
WO2021126695	LILLY CO ELI [US]	Incretin analogs and uses thereof
WO2021140209	INST NAT SANTE RECH MED [FR]; CENTRE NAT RECH SCIENT [FR]; UNIV COTE D'AZUR [FR]	Rspo1 proteins and their use
WO2021126584	AKSTON BIOSCIENCES CORP [US]	Ultra-long acting insulin-Fc fusion proteins and methods of use
WO2021116292	NOVO NORDISK AS [DK]	Novel insulin analogues and uses thereof
WO2021116290	UNIV AARHUS [DK]; REGION MIDTJYLLAND [DK]	Compounds for treatment of eye diseases
WO2021173900	AVM BIOTECHNOLOGY LLC [US]	Lymphocyte population and methods for producing same
WO2021163369	HCW BIOLOGICS INC [US]	Methods of treating age-related and inflammatory diseases
WO2021178483	UNIV DUKE [US]	Proteins with predictable liquid-liquid phase separation

Sistema Nervioso

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2021172863	UNIV EWHA IND COLLABORATION [KR]	Molecular diagnostic test for Alzheimer's disease
WO2021172864	UNIV EWHA IND COLLABORATION [KR]; GWANGJU INST SCIENCE & TECH [KR]	Alzheimer's disease diagnosis and prediction using epigenetic methylation modification of gene
WO2021173802	UNIV GEORGIA [US]; UNIV GRONINGEN [NL]	Chemically-stabilized allosteric modulators of leucine-rich repeat kinase 2 (LRRK2)
WO2021172925	RZNOMICS INC [KR]	Trans-splicing ribozyme specific to APOE4 RNA and use thereof
WO2021168183	IONIS PHARMACEUTICALS INC [US]	Methods for reducing HTT expression
WO2021167919	UNIV NORTH CAROLINA CHAPEL HILL [US]	AAV capsid-promoter interactions and cell selective gene expression
WO2021167723	UNIV TEXAS [US]	Chimeric scavenger receptors targeted to phosphorylated Tau (pTau) and uses thereof
WO2021163272	UNIV CALIFORNIA [US]	Platelet factors and cognitive improvement
WO2021163556	CHILDRENS HOSPITAL PHILADELPHIA [US]	Compositions and methods for inducible alternative splicing regulation of gene expression
WO2021162114	MIYATO MITSURU [JP]; OCHIYA TAKAHIRO [JP]; INT SPACE MEDICAL CO LTD [JP]	Method for producing extracellular vesicles and utilization thereof
WO2021162426	SAMSUNG LIFE PUBLIC WELFARE FOUNDATION [KR]	Method for producing mesenchymal stem cells for prevention or treatment of brain neuronal diseases, comprising ghrelin treatment, and use thereof
WO2021156831	BIORCHESTRA CO LTD [KR]	miRNA-485 inhibitor for gene upregulation
WO2021156832	BIORCHESTRA CO LTD [KR]	Use of miRNA-485 inhibitors for treating amyotrophic lateral sclerosis (ALS)
WO2021155867	TALNGEN INT LTD [CN]	Method and drug for preventing and treating multiple sclerosis
WO2021155296	PAROS BIO INC [US]	Gene therapy for neurodegenerative disorders using polynucleotide silencing and replacement

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2021151011	KAKU HIROAKI [US]; ROTHSTEIN THOMAS L [US]; THE BOARD OF TRUSTEES OF WESTERN MICHIGAN UNIV [US]	Treatment of neurodegenerative proteinopathies using Fas apoptosis inhibitory molecule (FAIM) or a fragment and/or a mimetic thereof
WO2021142163	SELONTERRA INC [US]	Treatment of Alzheimer's disease
WO2021137245	TECHNION RES & DEV FOUNDATION [IL]	Conus-based toxin peptides, nucleic acids encoding same and uses thereof in modulating NMDA receptors
WO2021137366	NAT UNIV GYEONGSANG IACF [KR]	Composition for predicting stage of Alzheimer's disease, and prediction kit using composition
WO2021127886	UNIV TSINGHUA [CN]	Development of dual-gRNA approach with undetectable off-target effect to correct C9ORF72 repeat expansion and C9ORF72 pathology
WO2021132201	UNIV OSAKA [JP]	Prophylactic or therapeutic agent for demyelinating disease
WO2021127455	ASKLEPIOS BIOPHARMACEUTICAL INC [US]; UNIV NORTH CAROLINA CHAPEL HILL [US]	Methods for treating Huntington's disease
WO2021127008	UNIV CALIFORNIA [US]	Compositions and methods for treating neuromuscular disorders
WO2021125762	SEASUN THERAPEUTICS [KR]	Composition for preventing or treating dementia, containing peptide nucleic acid complex with blood-brain barrier penetration ability as active ingredient
WO2021125352	MORI MASASHI [JP]	Method for synthesizing celosianin II, method for synthesizing betaxanthin, amyloid- β polymerization inhibitor or therapeutic or prophylactic agent for Alzheimer's disease, amyloid peptide aggregation inhibitor, and HIV-1 protease activity inhibitor
WO2021125349	RIKEN [JP]; CENTRAL INST FOR EXPERIMENTAL ANIMALS [JP]; UNIV HIROSHIMA [JP]	Non-human primate Alzheimer's disease model animal and method for producing same
WO2021115141	NANJING YOUZHIYUAN PHARMACEUTICAL TECH CO LTD [CN]	siRNA for inhibiting HTT gene expression, and precursor and application thereof
WO2021114164	SHENZHEN INST OF ADV TECH CAS [CN]	Exosome, preparation method therefor and use thereof

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2021113394	THE INST FOR ETHNOMEDICINE DBA BRAIN CHEMISTRY LABS [US]	Methods of detection and analysis of nucleic acid in neural-derived exosomes
WO2021112220	UNIV MIYAZAKI [JP]; FOUNDATION FOR BIOMEDICAL RES AND INNOVATION AT KOBE [JP]	Therapeutic agent for neurodegenerative disease with abnormal protein accumulation
WO2021111981	LIFE QUALITY KENKYUJYO CO LTD [JP]	Agent for prevention or remediation of dementia and composition containing same
WO2021108869	UNIV WESTERN AUSTRALIA [AU]; UNIV MURDOCH [AU]	A biomarker and uses therefor
WO2021104094	SHENZHEN INST OF ADV TECH CAS [CN]	Neurodegenerative disease marker, chromogranin B, and use thereof
WO2021162565	UNIV WARSZAWSKI [PL]	Method of detecting protein monomers and aggregates, use of thioflavin T for detecting protein monomers and aggregates, thioflavin T for use in diagnosis of a disease associated with protein aggregation, optical system for detecting protein monomers and aggregates and method of generating amplified spontaneous emission of thioflavin T
WO2021167964	ALECTOR LLC [US]	PILRA antibodies and methods of use thereof
WO2021163369	HCW BIOLOGICS INC [US]	Methods of treating age-related and inflammatory diseases
WO2021159008	MAZE THERAPEUTICS INC [US]	Compositions and methods for treating neurodegenerative diseases
WO2021170659	OTTO MARKUS [DE]	Diagnosing a disease associated with synaptic degeneration using an ELISA for determining a beta-synuclein concentration in CSF
WO2021154941	ALNYLAM PHARMACEUTICALS INC [US]	Complement component C5 iRNA compositions for use in the treatment of amyotrophic lateral sclerosis (ALS)
WO2021142318	SYSTEM1 BIOSCIENCES INC [US]	Methods and compositions of pro-organ formation on particle substrates and uses thereof
WO2021146256	DENALI THERAPEUTICS INC [US]	Anti-TREM2 antibodies and methods of use thereof
WO2021160464	UNIV SHEFFIELD [GB]	Gene therapy

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2021140215	INST NAT SANTE RECH MED [FR]; CENTRE NAT RECH SCIENT [FR]; UNIV SORBONNE [FR]	NPTN65 is a new target for the treatment of tauopathies
WO2021113390	SHAPE THERAPEUTICS INC [US]	Compositions for treatment of diseases
WO2021140140	ALPHABETA AB [SE]	Compound and method for treatment of Alzheimer's disease
WO2021113270	SHAPE THERAPEUTICS INC [US]; HUSS DAVID [US]; MALI PRASHANT [US]	Therapeutic editing
WO2021130267	UNIV FREIBURG ALBERT LUDWIGS [DE]	Gut microbiota-related methods for treating dementia and age-dependent cognitive decline
WO2021118374	GDANSKI UNIV MEDYCZNY [PL]	Intrathecal administration of T regulatory cells in the treatment of multiple sclerosis
WO2021123428	CENTRE HOSPITALIER UNIV VAUDOIS CHUV [CH]	Methods for classification and treatment of psychotic disorder subjects
WO2021123378	4D PHARMA RES LTD [GB]	Compositions comprising bacterial strains
WO2021123143	CENTRE NAT RECH SCIENT [FR]; INST NAT SANTE RECH MED [FR]; COMMISSARIAT ENERGIE ATOMIQUE [FR]; UNIV BORDEAUX [FR]; CHU DE BORDEAUX [FR]; INRIA INST NAT RECH INFORMATIQUE & AUTOMATIQUE [FR]	An ubiquitin ligase inhibitor for use for preventing and/or treating a disease linked with cerebral hypoperfusion
EP3831844	PRINDEX S R L [IT]	Diagnosis and therapy of multiple sclerosis
EP3879272	UNIV FREIBURG ALBERT LUDWIGS [DE]	Gut microbiota-related methods for treating dementia and age-dependent cognitive decline
EP3839072	LUXIA SCIENT [FR]	Bacterial combinations predictive of the activity of multiple sclerosis
WO2021119217	WISCONSIN ALUMNI RES FOUND [US]; ZHANG SU CHUN [US]; FATHI ALI [US]	Chemical cocktail for inducing senescence in human neurons to promote disease modeling and drug discovery

Sistema Inmune

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2021168079	PANDION OPERATIONS INC [US]	Tissue targeted immunotolerance with a CD39 effector
WO2021168040	ASPIRA WOMENS HEALTH INC [US]	Compositions for endometriosis assessment having improved specificity
WO2021168363	PREDICTIVE TECH GROUP INC [US]; ALBERTSEN HANS [US]; CHETTIER RAKESH [US]; WARD KENNETH [US]	Systems and methods related to cancer
WO2021167310	PICO ENTECH CO LTD [KR]	Atopy inhibitory composition containing aldehyde dehydrogenase
WO2021164722	JIANGSU HENGRUI MEDICINE CO [CN]; SHANGHAI SHENGDI PHARMACEUTICAL CO LTD [CN]	Anti-IL-2 antibody, and antigen-binding fragment thereof and medical use thereof
WO2021164717	BIO THERA SOLUTIONS LTD [CN]	Anti-TNF- α antibody preparation, preparation method therefor and use thereof
WO2021163672	UNIV CORNELL [US]	Transferable microbiota for the treatment of ulcerative colitis
WO2021158092	KOREA ADVANCED INST SCI & TECH [KR]	Novel polypeptide capable of binding to complement component C3a, and uses thereof
WO2021154017	VIROCURE INC [KR]	Composition for preventing or treating inflammatory diseases of digestive system or colitis, comprising reovirus as active ingredient
WO2021147923	EV CELL BIOTECH GUANGZHOU CO LTD [CN]	Vesicle and use thereof
WO2021150066	NAT MARINE BIODIVERSITY INSTITUTE OF KOREA [KR]	Pharmaceutical composition comprising small octopus-derived peptide for treatment of inflammatory disease
WO2021149015	APRILBIO CO LTD [KR]	Multispecific antibodies, compositions comprising the same, and vectors and uses thereof
WO2021143573	JENKEM TECH CO LTD TIANJIN [CN]	Disubstituted pegylated interleukin 2, preparation method therefor and use thereof
WO2021146562	UNIV NEBRASKA [US]; AHMAD RIZWAN [US]	Anti-MAA immunoglobulin isotypes in inflammatory bowel disease: diagnostic implications for ulcerative colitis

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2021146458	PROTAGONIST THERAPEUTICS INC [US]	Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2021146454	JANSSEN BIOTECH INC [US]; PROTAGONIST THERAPEUTICS INC [US]	Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2021145700	TOOLGEN INC [KR]	Cells having high adaptability under hypoxic conditions, and use thereof
WO2021146644	SECOND GENOME INC [US]; RAVICHANDAR JAYAMARY DIVYA [US]; HAN ANDREW WONHEE [US]; DESANTIS TODD ZACHARY [US]; CHOW CHERYL EMILIANE T [US]	Methods and compositions for treating ulcerative colitis
WO2021142573	DING BANG [CN]	Fusion protein and preparation method and application thereof
WO2021146481	SYNTHEKINE INC [US]	IL2 muteins
WO2021142373	PROTAGONIST THERAPEUTICS INC [US]; GUPTA SUNEEL KUMAR [US]; MODI NISHIT BACHULAL [US]	Methods for treating inflammatory bowel diseases with $\alpha 4\beta 7$ integrin antagonists
WO2021139766	HUANG CHIH HUNG [CN]	Peptide interacting with toll-like receptor 2 and the composition comprising the same
WO2021130647	S A PHARMACHEM PRIVATE LTD [IN]	Probiotic formulations for liver and oral health and enhancement of immunity
WO2021127598	ICAHN SCHOOL MED MOUNT SINAI [US]	Compositions and methods for treating inflammatory bowel disease
WO2021127589	CHILDRENS HOSPITAL PHILADELPHIA [US]	Novel druggable targets for the treatment of inflammatory diseases such as systemic lupus erythematosus (SLE) and methods for diagnosis and treatment using the same
WO2021113989	UNIV MCMASTER [CA]	Method of diagnosing and treatment monitoring of Crohn's disease and ulcerative colitis
WO2021110127	CHEER GLOBAL LTD [CN]	Method of treating inflammatory bowel disease
WO2021112615	UNIV AJOU IND ACADEMIC COOP FOUND [KR]	Composition containing peptide or peptide compound as active ingredient, and medical use therefor
WO2021112614	UNIV AJOU IND ACADEMIC COOP FOUND [KR]	Pharmaceutical composition for preventing or treating Behcet's disease and rheumatoid arthritis, containing peptide or mixture thereof as active ingredient
WO2021110064	JIANGYIN USUN BIOCHEMICAL TECH CO LTD [CN]	New multi-functional oligopeptides

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2021108728	SERES THERAPEUTICS INC [US]	Designed bacterial compositions and uses thereof
WO2021108694	CEDARS SINAI MEDICAL CENTER [US]	Predicting extraintestinal manifestations of inflammatory bowel disease
EP3868777	INSTITUT NATIONAL DE RECH POUR LAGRICULTURE LALIMENTATION ET LENVIRONNEMENT [FR]	Immunogenic composition
WO2021175998	INSTITUT NATIONAL DE RECH POUR LAGRICULTURE LALIMENTATION ET LENVIRONNEMENT [FR]; HOPITAUX PARIS ASSIST PUBLIQUE [FR]; UNIV SORBONNE [FR]; INST NAT SANTE RECH MED [FR]	<i>Coprococcus</i> bacteria for use in the treatment of metabolic syndrome and inflammatory bowel diseases
WO2021155132	UNIV WASHINGTON [US]; AMGEN INC [US]	De novo stable, modular PD-1 binding proteins and oligomeric variants
WO2021142279	EVELO BIOSCIENCES INC [US]	Compositions and methods of treatment using <i>Veillonella parvula</i>
WO2021156310	INST NAT SANTE RECH MED [FR]; CENTRE NAT RECH SCIENT [FR]; UNIV AIX MARSEILLE [FR]	TAF4A4 polypeptide or polynucleotide for treating inflammatory disease
WO2021128027	REMEGEN CO LTD [CN]	TACI-Fc fusion protein and use thereof
WO2021130537	VERSAMEB AG [CH]	Compositions and methods for simultaneously modulating expression of genes
WO2021144457	GENMAB AS [DK]	Formulations of CD38 antibodies and uses thereof
WO2021124369	OSPEDALE PEDIATRICO BAMBINO GESU [IT]	Circulating micro-RNAs as biomarkers for the diagnosis of celiac disease and for monitoring adherence to a gluten-free diet
WO2021136840	PEPTINOV [FR]; CONSERVATOIRE NAT DES ARTS ET METIERS [FR]	Immunogenic conjugate intended to induce an immune response directed against interleukin-6
WO2021122867	NOVOZYMES AS [DK]	Xylanase variants and polynucleotides encoding same
WO2021123173	HOFFMANN LA ROCHE [CH]; UNIV MONASH [AU]; HOFFMANN LA ROCHE [US]	IL-37 fusion proteins and uses thereof
WO2021129998	EVONIK OPERATIONS GMBH [DE]	Bacterial consortium comprising at least one bacillus and lactobacillus strain for gluten degradation
WO2021129997	EVONIK OPERATIONS GMBH [DE]	Process to identify consortia of probiotic strains suitable for gluten degradation
WO2020096695	APPLIED MOLECULAR TRANSP INC [US]; MRSNY RANDALL J [US]; OLSON CHARLES [US]; MACLEAN DEREK [US]; POSTLETHWAITE SALLY [US]	Cholix-derived carriers for oral delivery of heterologous payload

Nº PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2021127261	MASSACHUSETTS GEN HOSPITAL [US]	Engineered immune cells with reduced toxicity and uses thereof
WO2021154216	ALEXION PHARMA INC [US]	Fusion proteins and methods of treating complement dysregulation using the same
WO2021136392	SHANGHAI HAILU BIOLOGICAL TECH CO LTD [CN]	LAG-3 antibody and medical use thereof
WO2021173900	AVM BIOTECHNOLOGY LLC [US]	Lymphocyte population and methods for producing same
WO2021167964	ALECTOR LLC [US]	PILRA antibodies and methods of use thereof
WO2021156504	NURITAS LTD [IE]	Treatment of PANX1 associates diseases
WO2021119400	ALECTOR LLC [US]	Methods of use of anti-CD33 antibodies
WO2021163369	HCW BIOLOGICS INC [US]	Methods of treating age-related and inflammatory diseases
WO2021115240	SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD [CN]; HARBOUR BIOMED SUZHOU CO LTD [CN]	Anti-TSLP antibody and uses thereof

Noticias

SESIONES DE FORMACIÓN DE LA OMPI, RELATIVAS A LA NUEVA NORMA ST.26 Y LA HERRAMIENTA WIPO SEQUENCE QUE FACILITA LA PREPARACIÓN DE LAS LISTAS DE SECUENCIAS DE SOLICITUDES DE PATENTES

La Oficina Internacional de la Organización Mundial de la Propiedad Intelectual (OMPI) ha estado trabajando en la elaboración de su nueva herramienta informática, WIPO Sequence, que permite a los solicitantes de patentes y a las oficinas de Propiedad Industrial preparar y verificar las listas de secuencias de aminoácidos y nucleótidos como parte de las solicitudes de patente nacionales o internacionales de acuerdo con la nueva Norma ST.26 de la OMPI, cuya aplicación está prevista en 2022.

Con el fin de dar apoyo a las Oficinas y a los solicitantes de patentes en la transición al uso de la Norma ST.26, la OMPI está realizando una serie de seminarios de formación por vía telemática (webinarios) en español con la colaboración de la Oficina Española de Patentes y Marcas, O.A. (OEPM).

La documentación del primer seminario en español (“Introducción”), se puede descargar en el siguiente enlace.

https://www.wipo.int/meetings/en/details.jsp?meeting_id=65771

Los detalles sobre cómo inscribirse en estos webinarios se encuentran disponibles en el sitio web de la OMPI

NUEVOS CONVENIOS FIRMADOS POR LA OEPM

La colaboración entre instituciones resulta fundamental para el avance de la sociedad en general y de la economía del país. Desde la OEPM esto lo tenemos muy claro, y por ello impulsamos la firma de diferentes convenios con distintas entidades de ámbitos tan diversos como la alimentación, el agua, los muebles y metales, el plástico o la energía solar entre otros.



La finalidad de estos convenios es impulsar la competitividad de la industria española en el ámbito de la innovación y su protección mediante la Propiedad Industrial (PI). Para ello, en sus correspondientes resoluciones se contempla la realización de actividades conjuntas, entre otras las

jornadas formativas sobre los derechos de PI, que pretenden dar a conocer la utilización de los servicios de información tecnológica que ofrece la OEPM, los mecanismos de protección de los resultados de investigación y desarrollo tecnológico. Además, la OEPM les ofrece el apoyo necesario en la protección de sus activos intangibles con el fin de facilitar, impulsar y estimular el conocimiento y la utilización de los derechos de PI.

Sin duda alguna, estos convenios van a resultar una herramienta de cooperación muy útil para la promoción de la PI y sus beneficios en el desarrollo científico, económico y social de nuestro país.

Más información

La Oficina Española de Patentes y Marcas, O.A., y la Federación Española de Industrias de Alimentación y Bebidas (FIAB) firman un nuevo convenio de colaboración

La OEPM firma cuatro nuevos convenios de colaboración en materia de propiedad industrial con las siguientes plataformas y asociaciones tecnológicas: AIMPLAS, PLATECMA, PTECO2 y SOLAR CONCENTRA – PROTERMOSOLAR

La OEPM y la Plataforma Tecnológica Española del Agua firman un nuevo convenio de colaboración en materia de Propiedad Industrial

Nuevo convenio de colaboración entre la OEPM y el Instituto Tecnológico Metalmecánico, Mueble, Madera, Embalaje y afines, para impulsar la Propiedad Industrial dentro de la plataforma Tecnológica Forestal Española, PTFOR

CÓMO PROTEGER TUS DERECHOS DE PROPIEDAD INDUSTRIAL (DPI) SI ERES UNA PYME, EMPRESA O EMPRENDEDOR

¿Sabrías cómo proceder si infringen uno de tus Derechos de Propiedad Industrial?

La Oficina Española de Patentes y Marcas, O.A. (OEPM) ha publicado recientemente un folleto que recoge las pautas de cómo actuar y defenderse si sufrimos vulneración de una creación que implique un Derecho de Propiedad Industrial (DPI): una marca, un diseño, o una invención.

Dividido en cuatro líneas principales, el folleto desglosa qué medidas deben tomarse frente al uso no autorizado de terceros de nuestros DPI:

1. **Comenzando un negocio:** registra los activos intangibles para poder probar que son tuyos. Aprovecha los servicios de asesoramiento gratuitos que ofrece la OEPM, como el Servicio de Apoyo a la Empresa y evita los errores más comunes.
2. **Gestiona tu negocio:** infórmate sobre los servicios de vigilancia y haz un seguimiento activo del estado de tus DPI.
3. **Haz que tu negocio crezca:** infórmate de cómo proteger tus marcas, diseños e invenciones si vas a exportar o a exhibirlas en ferias o exposiciones. También valora la idoneidad de informar a aduanas.
4. **Defiende tu negocio:** se pueden tomar diversas vías y todas tienen ventajas e inconvenientes y debe decidirse cuál es la más adecuada según el caso. Muchas veces es una cuestión de elección del perjudicado de una vía u otra y otras veces, en función de dónde se produce la infracción o cuál es el resultado que se desea obtener. Por tanto, siempre es buena idea disponer de asesoramiento profesional. Se debe estudiar bien la situación y valorar costes y beneficios. Recabar todas las pruebas posibles de la presunta infracción. En el folleto también se ofrece una guía de actuación dependiendo del lugar donde se produce la infracción: en el mercado español, en la frontera de España, en el mercado interior de la Unión Europea, en terceros países o en el mundo digital.



Protege tu negocio. Mientras determinadas empresas apuestan por la calidad y la innovación de sus productos para crear valor añadido y diferenciarse de la competencia, existen agentes, en muchos casos mafias, que no dudan en infringir los derechos exclusivos y aprovecharse de la reputación ajena. Protege tus DPI, para que puedas defenderte y otros no se aprovechen de tus creaciones e invenciones.

El folleto puede descargarse [aquí](#) y también pueden visualizarse en el portal [Stopfalsificaciones](#).

VENTAJAS DE TRABAJAR EN LA OEPM

La Oficina Española de Patentes y Marcas, O.A. (OEPM) es un organismo dependiente del Ministerio de Industria, Comercio y Turismo dedicado a la Propiedad Industrial, de carácter dinámico y con vocación internacional.



¿Te interesaría trabajar en la OEPM? ¡Conoce las ventajas de trabajar en la OEPM!

Recientemente, se ha publicado un folleto explicativo y un catálogo en el que figuran los motivos por los que es atractivo trabajar en la Oficina Española de Patentes y

Marcas, O.A. (OEPM).

El objetivo de estos documentos no es otro que el de atraer talento y hacer más visible a la OEPM como destino para trabajar, dentro de un contexto de una competitividad cada vez mayor y unos recursos humanos cada vez más escasos.

Más información:

https://www.oepm.es/es/sobre_oepm/empleo/index.html

[Folleto Ventajas OEPM](#)

[Catálogo Ventajas OEPM](#)

